Muhareb, Amin
Blank, Antje http://orcid.org/0000-0001-8743-5194
Meid, Andreas D. http://orcid.org/0000-0003-3537-3205
Foerster, Kathrin I. http://orcid.org/0000-0001-8583-7181
Stoll, Felicitas http://orcid.org/0000-0003-3005-0546
Burhenne, Jürgen http://orcid.org/0000-0002-2190-1698
Haefeli, Walter E. http://orcid.org/0000-0003-0672-6876
Mikus, Gerd http://orcid.org/0000-0003-1783-133X
Clinical trials referenced in this document:
Documents that mention this clinical trial
CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults
https://doi.org/10.1007/s40262-023-01287-7
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Accepted: 29 June 2023
First Online: 28 July 2023
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL.
: No conflicts of interest have been declared by any author.
: The trial protocol was approved by the responsible ethics committee of the Faculty of Medicine of Heidelberg University (Afmo-431/2020) and the German competent authority (BfArM) on 13 July 2020 (EudraCT No: 2020-001017-20, registered on March 5th, 2020).
: The collected and analysed data can be made available upon reasonable request.
: Not applicable.
: Not applicable.
: Informed consent was obtained from all participants included in this trial prior to carrying out any trial procedures.
: G.M. proposed the research topic. A.M., A.B., F.S., G.M. and W.E.H. developed the trial protocol. A.M. and A.B. executed the trial. J.B. and K.I.F. analysed the samples. A.M., G.M. and A.D.M. performed the statistical analyses. A.M. wrote the first draft of the manuscript. All authors discussed and interpreted the results and contributed to the manuscript.